Award of Share Options

RNS Number : 3627B

Ergomed plc

30 January 2020

 

 PRESS RELEASE

Ergomed Award of Share Options

Guildford, UK - 30 January 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Incentive Plan) awards have been made to recently appointed Chief Operating Officer, Lewis Cameron.

On 29 January 2020, Mr Cameron was awarded a total of 250,000 share options over the Company's ordinary shares, having a nominal value of 1 pence each, with an exercise price of 1 pence per share (the "Options"). Of the total, 125,000 will vest three years after the commencement of Mr Cameron's employment with the Company and are not subject to performance criteria. The remaining 125,000 are subject to performance criteria and will vest dependent on total shareholder return of 15% per annum over three years.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Lewis Cameron
2	Reason for the notification
a)	Position/status	Chief Operating Officer and Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed Plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Grant of options under the Company's Long Term Incentive Plan
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		1 pence	250,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	250,000 ordinary shares at an exercise price of 1 pence per share.
f)	Date of the transaction	29 January 2020
g)	Place of the transaction	Outside a trading venue.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart	[e-mail]
Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

 

END

 

 

MSCFFFEFLFIAFII